Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer

Phase 2

Withdrawn

• Conditions: Advanced or Metastatic Biliary Tract Cancer
• Interventions: Drug: Varlitinib; Drug: Capecitabine

• Registration Number: NCT03129074
• Lead Sponsor: ASLAN Pharmaceuticals

Brief Summary

The purpose of the study is to assess the efficacy of varlitinib in combination with capecitabine as measured by objective response rate (ORR) assessed by independent central review (ICR), based on RECIST v1.1 criteria.

Detailed Description

Also to explore the role of biomarkers as predictors of response and clinical benefit with varlitinib

Study Timeline

• Study First Submitted: 2017-04-21
• Study First Submitted QC: 2017-04-25
• Study First Posted: 2017-04-26
• Status Verified: 2018-05
• Study Start: 2018-05
• Last Update Submitted: 2018-05-21
• Last Update Posted: 2018-05-23
• Primary Completion: 2020-03
• Study Completion: 2020-09

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Are of or older than the legal age in the respective countries at the time when written informed consent is obtained.

2. Are able to understand and willing to sign the informed consent form.

3. Have histologically confirmed diagnoses of relapsed, locally advanced (unresectable) or metastatic biliary tract cancer, including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer and carcinoma of Ampulla of Vater.

4. Have eligible tumor tissue (archival or fresh) for the evaluation of relevant primary endpoints.

   (Note: For patients without eligible tumor tissue, a discussion with the sponsor is mandatory).

5. Have radiographically measurable disease as determined by the investigator based on the RECIST v1.1 criteria.

6. Have no evidence of biliary duct obstruction, unless obstruction is controlled by local treatment or, in whom the biliary tree can be decompressed by endoscopic or percutaneous stenting with subsequent reduction in bilirubin to below 1.5 x upper level of normal (ULN).

7. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

8. Have an estimated life expectancy of more than 3 months, at the time of screening.

9. Have adequate organ and hematological function:

   1. Hematological function, as follows:

      • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
      • Platelet count ≥ 100 x 109/L

   2. Renal functions, as follows:

      • estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) > 50 mL/min/1.73m2

   3. Hepatic function, as follows:

      • Total bilirubin ≤ 1.5 x ULN
      • aspartate aminotransferase and alanine aminotransferase ≤ 5 x ULN

Exclusion Criteria

1. Have received systemic anti-cancer treatment except (neo-) adjuvant therapy for early stage disease.
2. Are currently on or have received radiation or local treatment within the past 4 weeks for the target lesion(s), prior to screening.
3. Had undergone major surgical procedures within 28 days prior to study cycle 1 day 1.
4. Have a metastatic brain lesion(s), including asymptomatic and well controlled lesion(s).
5. Have malabsorption syndrome, diseases significantly affecting gastrointestinal function, or difficulty in swallowing and retaining oral medications.
6. Have any history of other malignancy unless in remission for more than 1 year (skin carcinoma and carcinoma-in-site of uterine cervix treated with curative intent is not exclusionary).
7. Are female patients who are pregnant or breast feeding.
8. Have been previously treated with varlitinib or capecitabine.
9. Have received any investigational drug (or have used an investigational device) within the last 14 days before receiving the first dose of study medication.
10. Have unresolved or unstable serious toxicity (≥ CTCAE 4.03 Grade 2), with the exception of anemia, asthenia, and alopecia, from prior administration of another investigational drug and/or prior anti-cancer treatment.
11. Have a known positive test for human immunodeficiency virus, active viral hepatitis C, viral hepatitis B infection with hepatitis B virus DNA exceeding 2000 IU/mL.
12. Have a known history of drug addiction within last 1 year, on the basis of which there could be a higher risk of non-compliance to study treatment.
13. Need continuous treatment with proton pump inhibitors during the study period.
14. Have a history of (non-infectious) pneumonitis that required steroids or current pneumonitis, or with a history of interstitial lung disease or current interstitial lung disease.
15. Have any history or presence of clinically significant condition which in the opinion of the investigator could jeopardize the safety of the patient or the validity of the study results.
16. Have a baseline corrected QT interval > 450 ms or patients with known long QT syndrome, torsade de pointes, symptomatic ventricular tachycardia, unstable cardiac syndrome in the past 3 months before screening visit, > class 2 NYHA (The New York Heart Association Functional Classification heart failure), > grade 2 CCS (the Canadian Cardiovascular Society Guidelines) angina pectoris, or receiving quinidine, procainamide, disopyramide, amiodarone, dronedarone, arsenic, dofetilide, or sotalol methadone.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Varlitinib given in combination with capecitabine	Capecitabine	* PO varlitinib 300 mg BID * PO capecitabine 1000 mg/m2 BID
Varlitinib given in combination with capecitabine	Varlitinib	* PO varlitinib 300 mg BID * PO capecitabine 1000 mg/m2 BID

Primary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR)	Through study duration, estimated 3 years	Number (%) of patients with at least one visit response of CR or PR. Tumor evaluations will continue until the earlier of disease progression or starting a subsequent anti-cancer therapy.
Biomarker	Through study duration, estimated 3 years	Use Next generation sequencing/Immunohistochemistry to identify relationships between response to varlitinib and mutations or overexpression in human epidermal growth factor receptor (HER) receptors and the downstream signaling proteins, as well as, mutations in selected cancer pathways.

Secondary Outcome Measures

Name	Time	Method
Progression-free survival (PFS)	Through study duration, estimated 3 years	Defined as the time from start of treatment until the date of objective disease progression or death (by any cause in the absence of disease progression).
Overall survival (OS)	Through study duration, estimated 3 years	Defined as the time from start of treatment until death by any cause.
Duration of response (DoR)	Through study duration, estimated 3 years	Defined as the time, in days, from the first recorded achievement of a response (PR or above) until time of objective disease progression in the subset of patients classified as responders in the assessment of ORR
Disease control rate (DCR)	Through study duration, estimated 3 years	Defined as the proportion of patients with a best response of stable disease maintained for at least 12 weeks (-5 days), PR or CR as defined by RECIST v1.1 criteria.
Incidence of Adverse Events and changes from baseline in safety parameters	Through study duration, estimated 3 years	Incidence of Adverse Events, categorized in accordance to CTCAE 4.03 and changes from baseline in safety parameters (including vital signs, ECG parameters, clinical laboratory tests).
Objective response rate (ORR)	Through study duration, estimated 3 years	Defined as the proportion of patients with a best objective response (BOR) of complete response (CR) or partial response (PR), as assessed by the investigator defined by the RECIST v1.1 criteria.